Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C61313
http://purl.obolibrary.org/obo/NCIT_C61313
|
|---|---|
| Preferred Name | Denosumab |
| Definitions |
A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. |
|---|---|
| prefLabel | Denosumab
|
| label | Denosumab
|
| PDQ_Closed_Trial_Search_ID | 481348
|
| code | C61313
|
| Has_Target | |
| prefixIRI | NCIT:C61313
|
| in_subset |
See more
See less
|
| Display_Name | Denosumab
|
| Preferred_Name | Denosumab
|
| FDA_UNII_Code | 4EQZ6YO2HI
|
| Contributing_Source |
CTRP
FDA
PCDC
|
| Maps_To | Denosumab
|
| CAS_Registry | 615258-40-7
|
| NCI_Drug_Dictionary_ID | 481348
|
| Legacy Concept Name | Densosumab
|
| type | |
| ALT_DEFINITION | A type of monoclonal antibody being studied in the treatment of multiple myeloma (a cancer that forms in bones) and in the prevention and treatment of bone metastases (cancer that has spread to bone from another organ). Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. AMG 162 binds to the protein RANKL and helps keep bone from breaking down.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 481348
|
| Accepted_Therapeutic_Use_For | Osteolytic Bone Metastases of Solid Tumors
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1690432
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |